Influence of the Genetic Polymorphisms in the 5′ Flanking and Exonic Regions of CYP2C19 on Proguanil Oxidation

被引:12
作者
Satyanarayana, Chakradhara Rao Uppugunduri [1 ]
Devendran, Anichavezhi [1 ]
Jayaraman, Muthukumaran [3 ]
Mannu, Jayakanthan [3 ]
Mathur, Premendu P. [3 ]
Gopal, Shewade Deepak [1 ]
Rajagopal, Krishnamoorthy [2 ]
Chandrasekaran, Adithan [1 ]
机构
[1] Jawaharlal Inst Postgrad Med Educ & Res JIPMER, Dept Pharmacol, Pharmacogenom Lab, Pondicherry 605006, India
[2] Hop Robert Debre, INSERM, U763, F-75019 Paris, France
[3] Pondicherry Univ, Ctr Bioinformat, Pondicherry, India
关键词
CYP2C19; promoter; transcription; variant alleles; transcription factor; phenotype; docking; South Indian; S-MEPHENYTOIN; 4-HYDROXYLATION; IN-VITRO; C/EBP-ALPHA; OMEPRAZOLE; METABOLISM; GENOTYPE; PHENOTYPE; ALLELES;
D O I
10.2133/dmpk.24.537
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
CYP2C19 is a polymorphic enzyme which metabolizes several clinically important drugs including proguanil. Variation in the 5' regulatory region may influence CYP2C19 activity. This study evaluates the relationship between proguanil metabolic ratio and genetic variations of CYP2C19 in a South Indian population. Fifty unrelated healthy subjects were genotyped for CYP2C19 *2 and *3 alleles and the 5' flanking region of CYP2C19 was sequenced. Plasma concentrations of proguanil and cycloguanil were estimated by reverse phase HPLC after single oral doses (200 mg) of proguanil. In silico docking analysis of transcription factors binding to its sites in CYP2C19 5' regulatory region was performed. The mean metabolic ratios (proguanil/cycloguanil) were highest in *1/*2 or *1/*3 subjects and in *2/*2 or *2/*3 as compared to *1/*1 subjects. Subjects with promoter region variation -98T > C showed decrease in the metabolic ratios irrespective of other variation, which may explain the deviation from the genotype-phenotype association of CYP2C19. In silico analysis predicted alteration in the interaction of transcription factors to their binding sites in the presence of variant alleles. The results of this study would be useful in predicting interindividual differences in the metabolism of substrates of CYP2C19.
引用
收藏
页码:537 / 548
页数:12
相关论文
共 50 条
  • [41] The impact of CYP2C19 genotype on phenoconversion by concomitant medication
    de Jong, Laura M.
    Boussallami, Soukayna
    Sanchez-Lopez, Elena
    Giera, Martin
    Tushuizen, Maarten E.
    Hoekstra, Menno
    Hawinkels, Lukas J. A. C.
    Rissmann, Robert
    Swen, Jesse J.
    Manson, Martijn L.
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [42] Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects
    Kang, Pureum
    Cho, Chang-Keun
    Jang, Choon-Gon
    Lee, Seok-Yong
    Lee, Yun Jeong
    Choi, Chang-Ik
    Bae, Jung-Woo
    ARCHIVES OF PHARMACAL RESEARCH, 2023, 46 (05) : 438 - 447
  • [43] Evaluation of the influence of sex and CYP2C19 and CYP2D6 polymorphisms in the disposition of citalopram
    Fudio, Salvador
    Borobia, Alberto M.
    Pinana, Enrique
    Ramirez, Elena
    Tabares, Beatriz
    Guerra, Pedro
    Carcas, Antonio
    Frias, Jesus
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2010, 626 (2-3) : 200 - 204
  • [44] Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: Comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype
    Chang, M
    Dahl, ML
    Tybring, G
    Gotharson, E
    Bertilsson, L
    PHARMACOGENETICS, 1995, 5 (06): : 358 - 363
  • [45] Pharmacogenetic Prediction of Individual Variability in Drug Response Based on CYP2D6, CYP2C9 and CYP2C19 Genetic Polymorphisms
    Chaudhry, Shafqat Rasul
    Muhammad, Sajjad
    Eidens, Moritz
    Klemm, Marco
    Khan, Dilaware
    Efferth, Thomas
    Weisshaar, Maria-Paz
    CURRENT DRUG METABOLISM, 2014, 15 (07) : 711 - 718
  • [46] Association of CYP2B6, CYP3A5, and CYP2C19 Genetic Polymorphisms With Sibutramine Pharmacokinetics in Healthy Korean Subjects
    Kim, K. A.
    Song, W. K.
    Park, J. Y.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 86 (05) : 511 - 518
  • [47] No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma
    Vangsted, Annette J.
    Soeby, Karen
    Klausen, Tobias W.
    Abildgaard, Niels
    Andersen, Niels F.
    Gimsing, Peter
    Gregersen, Henrik
    Vogel, Ulla
    Werge, Thomas
    Rasmussen, Henrik B.
    BMC CANCER, 2010, 10
  • [48] Relationship between proguanil metabolic ratio and CYP2C19 genotype in a Caucasian population
    Hoskins, JM
    Shenfield, GM
    Gross, AS
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 46 (05) : 499 - 504
  • [49] Effects of CYP2D6 and CYP2C19 genetic polymorphisms and cigarette smoking on the pharmacokinetics of tolperisone
    Byeon, Ji-Young
    Cho, Chang-Keun
    Kang, Pureum
    Kim, Se-Hyung
    Jang, Choon-Gon
    Lee, Seok-Yong
    Lee, Yun Jeong
    ARCHIVES OF PHARMACAL RESEARCH, 2023, 46 (08) : 713 - 721
  • [50] Clinical Role of CYP2C19 Polymorphisms in Patients with Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency
    Groselj, Urh
    Tansek, Mojca Zerjav
    Podkrajsek, Katarina Trebusak
    Hovnik, Tinka
    Battelino, Tadej
    Dolzan, Vita
    ACTA CHIMICA SLOVENICA, 2016, 63 (01) : 33 - 37